We're on the cusp of the first generation of treatments for Alzheimer's Disease, but there's a great deal to do to prepare the UK for new dementia treatments.
Two treatments have been approved in the US and one of these, lecanemab, is under consideration by UK and European regulators. A third, donanemab, recently received positive data for slowing disease progression in early Alzheimer's disease and there are 140 further treatments in clinical trials.
Greg Smith MP was grateful to Alzheimer's Research UK Head of Policy Dr Susan Mitchell for coming to Parliament earlier to brief MPs on these developments.
